



**QPS LLC**  
Delaware Technology Park  
1 Innovation Way, Suite 200  
Newark, DE 19711, USA

**Email** [covid19study@qps.com.com](mailto:covid19study@qps.com.com)  
**Tel** +1 302 369 5601  
**Fax** +1 302 369 5602

Good Day,

The global COVID-19 Pandemic affects every American and every American business. We all need to get back to work. If your organization has a plan to assess the infection status of its staff or if you have a process in place to perform contact tracing, QPS can help by providing the molecular test.

QPS, LLC has an FDA Emergency Use Authorized (EUA) COVID-19 molecular assay for detection of SARS-CoV-2 available as a private contract service in the USA.

Features of the service include:

1. Onsite sample collection by trained nurses
2. All necessary Personal Protective Equipment (PPE)
3. All necessary collection material
4. 48-hour results turnaround

Sample analysis is being done in our CLIA facility in Newark, Delaware. We meet all the regulatory requirements for regulated, high-complexity CLIA testing and can collect and process samples from all 50 States.

Please find attached a synopsis of the QPS testing capability and the current CDC guidance on Occupational Medicine Surveillance, then contact us for a consultation at [Covid19study@qps.com](mailto:Covid19study@qps.com).

Kind regards,  
John L Kolman

John L Kolman, Ph.D.



Vice President, QPS LLC  
Global Head, Translational Medicine, QPS Holdings, LLC  
QPS LLC | Delaware Technology Park | 1 Innovation  
Way | Suite 200 | Newark | DE 19711 | USA  
Mob 302 763-2191 | Tel 302 369-5243  
Email [john.kolman@qps.com](mailto:john.kolman@qps.com) | Web [www.qps.com](http://www.qps.com)

[www.qps.com](http://www.qps.com)